BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38791582)

  • 1. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
    Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
    Li H; Yuan D; Sun M; Ping Q
    Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
    Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
    Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector.
    Rogers BE; Zinn KR; Lin CY; Chaudhuri TR; Buchsbaum DJ
    Cancer; 2002 Feb; 94(4 Suppl):1298-305. PubMed ID: 11877760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
    Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
    Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
    Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
    J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors.
    Zheng N; Dai W; Du W; Zhang H; Lei L; Zhang H; Wang X; Wang J; Zhang X; Gao J; Zhang Q
    Mol Pharm; 2012 May; 9(5):1175-88. PubMed ID: 22435704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
    Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
    BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
    Tasaki Y; Suzuki M; Katsushima K; Shinjo K; Iijima K; Murofushi Y; Naiki-Ito A; Hayashi K; Qiu C; Takahashi A; Tanaka Y; Kawaguchi T; Sugawara M; Kataoka T; Naito M; Miyata K; Kataoka K; Noda T; Gao W; Kataoka H; Takahashi S; Kimura K; Kondo Y
    Cancer Res; 2021 Apr; 81(7):1654-1666. PubMed ID: 33648930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
    Iwase Y; Maitani Y
    Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
    Zhang J; Jin W; Wang X; Wang J; Zhang X; Zhang Q
    Mol Pharm; 2010 Aug; 7(4):1159-68. PubMed ID: 20524673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
    Shen H; Hu D; Du J; Wang X; Liu Y; Wang Y; Wei JM; Ma D; Wang P; Li L
    Eur J Pharmacol; 2008 Dec; 601(1-3):23-9. PubMed ID: 18983839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells.
    Gailhouste L; Liew LC; Hatada I; Nakagama H; Ochiya T
    Cell Death Dis; 2018 May; 9(5):468. PubMed ID: 29700299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.
    Bahmani B; Uehara M; Ordikhani F; Li X; Jiang L; Banouni N; Ichimura T; Kasinath V; Eskandari SK; Annabi N; Bromberg JS; Shultz LD; Greiner DL; Abdi R
    EBioMedicine; 2018 Dec; 38():79-88. PubMed ID: 30497977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted paclitaxel-octreotide conjugates inhibited the growth of paclitaxel-resistant human non-small cell lung cancer A549 cells in vitro.
    Liu Y; Xia H; Wang Y; Han W; Qin J; Gao W; Qu X; Wang X
    Thorac Cancer; 2021 Nov; 12(22):3053-3061. PubMed ID: 34617400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
    Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR
    Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts.
    Celinski SA; Fisher WE; Amaya F; Wu YQ; Yao Q; Youker KA; Li M
    J Surg Res; 2003 Nov; 115(1):41-7. PubMed ID: 14572771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes.
    Dai W; Jin W; Zhang J; Wang X; Wang J; Zhang X; Wan Y; Zhang Q
    Pharm Res; 2012 Oct; 29(10):2902-11. PubMed ID: 22723122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors.
    Zheng N; Dai W; Zhang H; Wang X; Wang J; Zhang X; Wang K; Li J; Zhang Q
    J Drug Target; 2015 Jan; 23(1):67-78. PubMed ID: 25366085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.